PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
01-Mar-2023 ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents ImmunoGen
01-Mar-2023 Vivan Therapeutics Achieves Milestone for ECHS1 Therapeutics Discovery Vivan Therapeutics
01-Mar-2023 Cyntegrity and PwC Germany Join Forces to Offer Comprehensive Risk-Based Quality Management Solutions to the Pharmaceutical Industry Cyntegrity
01-Mar-2023 Ten new companies enter BioInnovation Institute’s Venture Lab program BioInnovation Institute (BII)
01-Mar-2023 Deprecated Yen attracting renewed international interest in Japanese pharma CPHI Japan 2023
01-Mar-2023 AMARIN AND CSL SEQIRUS ANNOUNCE EXCLUSIVE LICENSE & DISTRIBUTION AGREEMENT TO COMMERCIALIZE VAZKEPA® (Icosapent Ethyl) IN AUSTRALIA AND NEW ZEALAND AMARIN AND CSL SEQIRUS
01-Mar-2023 Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023 Mainz BioMed N.V.
28-Feb-2023 Santhera Secures Additional Funding Through a Private Placement of Shares and Upsizing of Existing Financing Arrangement Santhera Pharmaceuticals
28-Feb-2023 NuCana to Participate in Two Upcoming Investor Conferences NuCana plc
28-Feb-2023 iTeos to Present at Cowen 43rd Annual Health Care Conference iTeos Therapeutics, Inc.
28-Feb-2023 OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease OKYO Pharma
28-Feb-2023 ABPI response to the new Northern Ireland Brexit deal ABPI
28-Feb-2023 Rare and orphan disease expert Terebellum launches market access guide Terebellum
28-Feb-2023 MediClin AG: Disclosure of the preliminary figures of the 2022 financial year MediClin AG
28-Feb-2023 Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics Rhythm Pharmaceuticals
28-Feb-2023 New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease Sanofi
28-Feb-2023 Almirall opens the doors of its R&D centre to the biotech ZeClinics Almirall
28-Feb-2023 UK faces £50bn economic hit due to spiralling medicines levy Association of the British Pharmaceutical Industry (ABPI)
28-Feb-2023 Rare disease community call for their unified voice to be heard in the fight for equitable care Sanofi
28-Feb-2023 Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars Relief Therapeutics Holding SA